Changing somatostatin tone significantly affects hexarelin's GH-releasing effect, and somatostatin withdrawal can trigger a rebound GH release that hexarelin amplifies.
Timing matters for GHRPsSomatostatin withdrawal creates a window where hexarelin's GH-releasing effect is amplified
What the researchers found
Hexarelin's GH-releasing effect is significantly modulated by somatostatin tone, with somatostatin withdrawal amplifying the GH response to hexarelin.
Why it matters
Understanding the hexarelin-somatostatin interaction explains why GHRPs work best at certain times and informs optimal dosing strategies.
How the study worked
Clinical trial testing hexarelin GH response during various somatostatin states (high tone, low tone, withdrawal) in human subjects.
What this study cannot tell us
Clinical trial with artificial somatostatin manipulation. Natural somatostatin fluctuations may produce different interactions.
How to read the evidence
Strong clinical evidence from a controlled human study manipulating somatostatin states.
When this study was published
Published in 1997, informing current GHRP dosing timing recommendations.
The bigger picture
This study helped establish the clinical principle that GHRP timing matters — the somatostatin fluctuation cycle creates windows of enhanced responsiveness.
Questions still open
- Can GHRP dosing be timed to natural somatostatin troughs for maximum effect?
- Does chronic GHRP use alter the somatostatin cycle?
Common questions
When is the best time to take hexarelin?
What is somatostatin withdrawal?
Read the original research
Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
Clinical endocrinology, 47(5), 537-47
Citation
Massoud, A F; Hindmarsh, P C; Brook, C G. (1997). Interaction of the growth hormone releasing peptide hexarelin with somatostatin.. Clinical endocrinology, 47(5), 537-47.